Evidence map›Paper›PMID 42171620›Full record

ArticleMicrobial genomics2026

Genomic characterization of invasive

Poyen Liu, Anne-Kathryn Venero, Theresa Tran, Benjamin J Metcalf, Sopio Chochua, Yuan Li, Yung-Feng Huang, Maw-Sheng Lee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbial genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Poyen LiuInstitute of Medicine, Chung Shan Medical University, Taichung, Taiwan, ROC.
Anne-Kathryn VeneroDivision of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Theresa TranDivision of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Benjamin J MetcalfDivision of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Sopio ChochuaDivision of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Yuan LiDivision of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Yung-Feng HuangDepartment of Pediatrics, Fu Jen Catholic University Hospital, Fu Jen Catholic University, New Taipei City, Taiwan, ROC.
Maw-Sheng LeeInstitute of Medicine, Chung Shan Medical University, Taichung, Taiwan, ROC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the introduction of pneumococcal conjugate vaccines, the incidence of invasive pneumococcal disease (IPD) among children has decreased significantly. The distribution of IPD cases has shifted towards other vulnerable populations, including older adults and individuals with pre-existing medical conditions. Alongside this shift, there has also been a concurrent change in pneumococcal serotype distribution. Studies on the distribution of pneumococcal serotypes and antibiotic resistance patterns in the post-pneumococcal conjugate vaccine era, particularly following the coronavirus disease 2019 (COVID-19) pandemic, remain limited in the Asia-Pacific region. This study aims to investigate patient characteristics, pneumococcal serotype and antibiotic resistance profiles predicted by whole-genome sequencing among IPD patients in a public medical centre in southern Taiwan. A total of 61 IPD isolates were collected between 2015 and 2023. Serotype and antibiotic resistance were determined using whole-genome sequencing. The results showed that 47.5% of cases were in patients aged 65 years and older and 34.3% of cases involved patients with comorbid malignancy. The serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13) comprised 52.5% of the isolates. Overall, 26.2% of isolates were non-susceptible to penicillin (non-meningitis breakpoint). For the PCV13 serotypes, the non-susceptible rate to penicillin (non-meningitis breakpoint) was 43.8%. Phylogenetic analysis suggested recent emergence of a multi-drug resistant serotype34/ST9395 lineage. These findings suggest that the older adult population and those with pre-existing medical conditions, particularly malignancy, could benefit from targeted prevention efforts.

Indexed as

Pneumococcal InfectionsStreptococcus pneumoniaeAdultAgedAged, 80 and overAnti-Bacterial AgentsChild, PreschoolDrug Resistance, BacterialFemaleGenome, BacterialHumansMaleMicrobial Sensitivity TestsMiddle AgedPneumococcal VaccinesSerogroup13-valent pneumococcal vaccineAnti-Bacterial AgentsPneumococcal Vaccinesantimicrobial resistanceinvasive pneumococcal diseasepneumococcal conjugate vaccineserotype

Identifiers

PMID42171620
PMCPMC13196992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.